PURSUANT TO RULE 13a - 16 OR 15d - 16 OF


For the month of July, 2006


SkyePharma PLC

(Translation of registrant's name into English)


SkyePharma PLC, 105 Piccadilly, London W1J 7NJ England

(Address of principal executive office)


Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40F.

Form 20-F X      Form 40-F

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes         No X

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- _______


For Immediate Release                                            28 July 2006

                               SkyePharma PLC

LONDON, UK, 28 July 2006 -- In compliance with NASDAQ Marketplace Rule 4350
(b)1(B) SkyePharma PLC (Nasdaq: SKYE; LSE: SKP) announces that the independent
audit report included in the Company's UK Annual Report and Annual Report on
Form 20-F for the year ended 31 December 2005 contained an explanatory paragraph
relating to the Company's ability to continue as a going concern. Management
plans with regard to these matters are described in Note 1 to the financial
statements. The disclosure in this press release is required under the
aforementioned NASDAQ rule and does not represent any change to the Company's
Annual Reports for the year ended 31 December 2005.

For further information please contact:
SkyePharma PLC                                           +44 207 491 1777
Peter Laing, Director of Corporate Communications        +44 207 491 5124
Sandra Haughton, US Investor Relations                    +1 212 753 5780

Buchanan Communications                                  +44 207 466 5000
Tim Anderson

About SkyePharma
SkyePharma PLC develops pharmaceutical products benefiting from world-leading
drug delivery technologies that provide easier-to-use and more effective drug
formulations. There are now twelve approved products incorporating SkyePharma's
technologies in the areas of oral, injectable, inhaled and topical delivery,
supported by advanced solubilisation capabilities. For more information, visit

Certain statements in this news release are forward-looking statements and
are made in reliance on the safe harbour provisions of the U.S. Private
Securities Litigation Act of 1995. Although SkyePharma believes that the
expectations reflected in these forward-looking statements are reasonable, it
can give no assurance that these expectations will materialize. Because the
expectations are subject to risks and uncertainties, actual results may vary
significantly from those expressed or implied by the forward-looking statements
based upon a number of factors, which are described in SkyePharma's 20-F and
other documents on file with the SEC. Factors that could cause differences
between actual results and those implied by the forward-looking statements
contained in this news release include, without limitation, risks related to the
development of new products, risks related to obtaining and maintaining
regulatory approval for existing, new or expanded indications of existing and
new products, risks related to SkyePharma's ability to manufacture products on a
large scale or at all, risks related to SkyePharma's and its marketing partners'
ability to market products on a large scale to maintain or expand market share
in the face of changes in customer requirements, competition and technological
change, risks related to regulatory compliance, the risk of product liability
claims, risks related to the ownership and use of intellectual property, and
risks related to SkyePharma's ability to manage growth. SkyePharma undertakes no
obligation to revise or update any such forward-looking statement to reflect
events or circumstances after the date of this release.



     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

                                                                  SkyePharma PLC

                                                                      By: /s/ Douglas Parkhill

                                                                       Name: Douglas Parkhill
                                                                          Title: Company Secretary

Date:   July 28, 2006